Brought to you by 
Cell Genesys acquires fellow gene therapy co. Somatix
13 Jul 1999
Executive Summary
Cell Genesys acquired Somatix Therapy by exchanging 0.385 shares for each of Somatix's 24.4mm outstanding shares (about $3.40 per share, based on Cell Genesys' closing price the day of the deal's announcement) in a deal worth about $82.7mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cell Genesys acquires fellow gene therapy co. Somatix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice